Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal

Stryker received FDA 510(k) clearance for its Sonopet 3 device, designed with input from surgeons to enhance power, precision, and versatility in tissue removal. The platform includes advanced technologies like RISE and Pulse Control, aiming to streamline surgical workflows. Clinical use is expected to begin in October, with a full commercial launch later this fall, according to the company.

Stryker invested $400m in CMR Surgical, gaining exclusive US sales rights for CMR's Versius surgical robot. CMR retains global development and sales outside the US. The deal includes an option for Stryker to acquire CMR outright, pending regulatory approval. Both companies cite high demand for robotic-assisted surgery and Versius's modular design as key factors. The agreement is subject to regulatory clearance.

Stryker invested $400 million in CMR Surgical for exclusive US distribution rights to its Versius robotic surgery system, entering the soft tissue robotics market. The deal includes an option to acquire CMR Surgical. Versius is FDA-cleared for gallbladder procedures and has performed over 45,000 procedures globally. Stryker aims to expand robotic-assisted surgery access across hospitals and ASCs.

Stryker (NYSE:SYK) will invest $400 million in CMR Surgical, gaining exclusive U.S. sales rights for its Versius robotic surgery portfolio. The deal includes an option to acquire CMR Surgical. Analyst Steven Lichtman views this as a growth opportunity, aligning with the shift to outpatient procedures. Stryker shares were up 0.03% at $282.69 at the time of publication.

Stryker (SYK) invested $400M in CMR Surgical for U.S. rights to its Versius robotic surgery platform, with an option to acquire the company. The deal follows Medtronic's $700M investment in Cornerstone Robotics, highlighting competition in the soft-tissue robotics market. Versius is designed for easy integration into surgical programs and has FDA clearance for gallbladder removal procedures.

Stryker (SYK) invested $400m in CMR Surgical, a private UK surgical robotics firm, with an option to acquire it. The deal includes a US commercial agency agreement for CMR's Versius platform. Both companies aim to leverage the growing demand for robotic-assisted surgery. CMR will use the funds to accelerate innovation and global expansion.